Sugi Predict

Sugi Predict / Compounds / SCHEMBL1065187

SCHEMBL1065187

SCHEMBL1065187

Cc1cc(F)ccc1-c1nc(N(C)C(O)O)nc2c1ccc(=O)n2-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.38
▸ CYP1A2 P05177 3/20 0.38
▸ CASP1 P29466 3/20 0.38
▸ CASP7 P55210 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ USP2 O75604 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ MAPK14 Q16539 6/20 0.37
▸ MAPK13 O15264 5/20 0.37
▸ MAPK12 P53778 5/20 0.37
▸ MAPK11 Q15759 5/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ HSD17B10 Q99714 2/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ MAT2A P31153 2/20 0.36
▸ CTSA P10619 4/20 0.33
▸ DHODH Q02127 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1065191 0.81 CDK4 (0.35) ALDH1A1CYP1A2CASP1CASP7MEN1
SCHEMBL1060752 0.80 MAPK13 (0.36) ALDH1A1MEN1KMT2AMAPK14MAPK13
SCHEMBL1724218 0.80 MAPK14 (0.37) MAPK14MAPK13MAPK12MAPK11KCNH2
SCHEMBL1065734 0.80 MAT2A (0.37) ALDH1A1CYP1A2CASP1CASP7MEN1
SCHEMBL1064227 0.79 HSP90AB1 (0.44) ALDH1A1MEN1KMT2AMAPK14MAPK13
SCHEMBL1064575 0.79 MAT2A (0.38) MEN1KMT2AMAPK14MAPK13MAPK12
SCHEMBL5113184 0.78 SCN9A (0.39) ALDH1A1CYP1A2CASP1CASP7MEN1
SCHEMBL1067500 0.77 MAT2A (0.39) ALDH1A1CYP1A2CASP1CASP7MEN1
SCHEMBL1061200 0.73 MAPK14 (0.45) ALDH1A1CYP1A2CASP1CASP7MEN1
SCHEMBL5740341 0.73 MAPK14 (0.42) ALDH1A1CYP1A2CASP1CASP7MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209901-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2004-10-21 — — US claimed
US-20040116697-A1 Novel compounds GLAXOSMITHKLINE LLC 2004-06-17 — — US claimed
EP-2404603-A1 Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases Glaxosmithkline LLC (US) 2012-01-11 — — EP disclosed
US-8058282-B2 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy GLAXOSMITHKLINE LLC (US) 2011-11-15 — — US disclosed
US-20110046109-A1 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY GLAXOSMITHKLINE LLC (US) 2011-02-24 — — US disclosed
US-20110009625-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2011-01-13 — — US disclosed
US-7759486-B2 Substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-07-20 — — US disclosed
US-20090105478-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-04-23 — — US disclosed
US-20080032969-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2008-02-07 — — US disclosed
US-20080033170-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2008-02-07 — — US disclosed
US-7323472-B2 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-01-29 — — US disclosed
US-7314881-B2 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-01-01 — — US disclosed
US-7314934-B2 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates SMITHKLINE BEECHAM CORPORATION (US) 2008-01-01 — — US disclosed
US-20050203109-A1 Novel Compounds SMITHKLINE BEECHAM CORPORATION 2005-09-15 — — US disclosed
US-20040209901-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2004-10-21 — — US disclosed
US-20040116697-A1 Novel compounds GLAXOSMITHKLINE LLC 2004-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105478-A1 NOVEL COMPOUNDS MAPKAPK2, CREBBP, CDC42BPB ALDH1A1 4362/4885CYP1A2 4733/4885CASP1 2494/4885
US-20080033170-A1 NOVEL COMPOUNDS MAPKAPK2, CREBBP, CDC42BPB ALDH1A1 4362/4885CYP1A2 4733/4885CASP1 2494/4885
US-20110046109-A1 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY MAPKAPK2, MAPK8, CREBBP ALDH1A1 4185/4885CYP1A2 4530/4885CASP1 2478/4885
US-20080032969-A1 NOVEL COMPOUNDS MAPKAPK2, CREBBP, CDC42BPB ALDH1A1 4362/4885CYP1A2 4733/4885CASP1 2494/4885
US-20110009625-A1 NOVEL COMPOUNDS MAPKAPK2, CREBBP, CDC42BPB ALDH1A1 4362/4885CYP1A2 4733/4885CASP1 2494/4885
US-20040209901-A1 Novel compounds MAPKAPK2, MAPKAPK3, MAPK7 ALDH1A1 4298/4885CYP1A2 4630/4885CASP1 2412/4885
US-20050203109-A1 Novel Compounds MAPKAPK2, CREBBP, CDC42BPB ALDH1A1 4362/4885CYP1A2 4733/4885CASP1 2494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.